Lexaria
Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative DehydraTECH(TM)
platform works to deliver chemical compounds to the bloodstream at speeds
similar to inhalation methods, offering an alternative to smoking. An article
discussing the company further reads, “Lexaria’s noncombustion-based,
noninhalation-based delivery method requires no chemicals or additives. . . .
‘We use a patented dehydration synthesis process to combine the nicotine with
simple ingredients like sunflower oil in a unique way,’ CEO Chris Bunka
told Forbes (http://ibn.fm/uCoMP).
‘It allows for the removal of the bitter taste often associated with nicotine
without the need for artificial flavors that are often appealing to children.
Moreover, tested in animals in 2018, we proved that DehydraTECH could deliver
nicotine to the bloodstream of an animal in as little as two minutes. The fact
that it is fast means that smokers might not be frustrated waiting for their
nicotine experience to begin, the way they have been with traditional nicotine
products such as gums and lozenges.’
To view the full article, visit http://ibn.fm/Q7ulJ
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a global innovator in
drug-delivery platforms. Its patented DehydraTECH(TM) drug-delivery technology
changes the way active pharmaceutical ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher
effectiveness for lipophilic active molecules. DehydraTECH increases
bio-absorption, reduces time of onset and masks unwanted tastes for orally
administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules.
Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry
for use in cannabinoid beverages, edibles and oral products, as well as to a
world-leading tobacco producer for the development of smokeless, oral-based
nicotine products. Lexaria operates a licensed, in-house research laboratory
and holds a robust intellectual property portfolio with 16 patents granted and
over 60 patents pending worldwide. For more information, visit the company’s
website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
